Resetting After Your Lead Drug Fails
Santhera CEO On Transparency In The Face Of Adversity
Executive Summary
Becoming a first-time CEO of a biotech company in 2020 meant dealing with unexpected challenges without any instruction book to follow. Santhera Pharmaceuticals’ Dario Eklund not only had COVID-19 upheaval to manage, but also a late-stage trial failure, a virtual financing and a new plan for the company to sell to stakeholders.
You may also be interested in...
Santhera Pulls EU Filing For Failed DMD Candidate
Swiss company Santhera's lengthy and problem-laden journey to repurpose its already marketed idebenone for use in Duchenne Muscular Dystrophy has ended in failure. The company has withdrawn its EU filing for the product following its announcement that it was halting development.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.